SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Jetstar to Charge for Overhead Cabin Bags From February 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
SOUTH SAN FRANCISCO, Calif., March 15, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on March 12, 2018, the compensation committee of the Company’s board of directors granted David L. Johnson an option to purchase 55,000 shares of the Company’s common stock with a per share exercise price of $54.05, the closing trading price on the grant date, and a restricted stock unit award for 35,000 shares of the Company’s common stock. All of the above-described awards were made under the Company’s 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to Mr. Johnson entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock options and restricted stock unit awards described above) for issuance under the Plan, which was approved by the Company’s board of directors in January 2017.
About Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
